168 related articles for article (PubMed ID: 1778317)
1. Comparison of toxicities of acellular pertussis vaccine with whole cell pertussis vaccine in experimental animals.
Sato Y; Sato H
Dev Biol Stand; 1991; 73():251-62. PubMed ID: 1778317
[TBL] [Abstract][Full Text] [Related]
2. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
Gupta RK; Saxena SN; Sharma SB; Ahuja S
Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314
[TBL] [Abstract][Full Text] [Related]
3. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
[TBL] [Abstract][Full Text] [Related]
4. Comparative biological activities of acellular pertussis vaccines produced by Kitasato.
Watanabe M; Izumiya K; Sato T; Yoshino K; Nakagawa N; Ohoishi M; Hoshino M
Kitasato Arch Exp Med; 1991 Apr; 64(1):31-42. PubMed ID: 1798236
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis.
Morokuma K; Ginnaga A; Nishihara T; Tsunoda S; Furukawa M; Aihara K; Sakoh M
Dev Biol Stand; 1991; 73():223-32. PubMed ID: 1685713
[TBL] [Abstract][Full Text] [Related]
6. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H
Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528
[TBL] [Abstract][Full Text] [Related]
7. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers.
Sato Y; Sato H
Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530
[TBL] [Abstract][Full Text] [Related]
8. A novel bivalent acellular pertussis vaccine based on the 69 kDa protein and FHA.
Novotny P; Chubb AP; Cownley K; Charles IG
Dev Biol Stand; 1991; 73():243-9. PubMed ID: 1778316
[TBL] [Abstract][Full Text] [Related]
9. Potency assay and characterization of lymphocytosis promoting factor in whole cell and acellular pertussis vaccines.
Tiru M; Falk A; Brym-Grynblat B; Pettersson IM
Dev Biol Stand; 1991; 73():157-65. PubMed ID: 1778309
[TBL] [Abstract][Full Text] [Related]
10. Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines.
Gupta RK; Anderson R; Cecchini D; Rost B; Griffin P; Benscoter K; Xu J; Montanez-Ortiz L; Siber GR
Dev Biol Stand; 1996; 86():283-96. PubMed ID: 8785957
[TBL] [Abstract][Full Text] [Related]
11. Differences in antibody response to whole-cell pertussis vaccines.
Edwards KM; Decker MD; Halsey NA; Koblin BA; Townsend T; Auerbach B; Karzon DT
Pediatrics; 1991 Nov; 88(5):1019-23. PubMed ID: 1945605
[TBL] [Abstract][Full Text] [Related]
12. Modified intra-cerebral challenge assay for acellular pertussis vaccines: comparisons among whole cell and acellular vaccines.
Gaines-Das R; Horiuchi Y; Zhang SM; Newland P; Kim Y; Corbel M; Xing D
Vaccine; 2009 Nov; 27(49):6824-32. PubMed ID: 19765397
[TBL] [Abstract][Full Text] [Related]
13. Aerosol infection test for evaluation of pertussis vaccine.
Syukuda Y; Watanabe H; Suehara A; Fujii S; Kuno-Sakai H; Kimura M
Tokai J Exp Clin Med; 1988; 13 Suppl():71-7. PubMed ID: 2908529
[TBL] [Abstract][Full Text] [Related]
14. [The immunological basis of the administration of DTP-polio vaccine].
Cohen H
Verh K Acad Geneeskd Belg; 2000; 62(4):245-67. PubMed ID: 11004905
[TBL] [Abstract][Full Text] [Related]
15. Collaborative study for the standardisation of the histamine sensitizing test in mice and the CHO cell-based assay for the residual toxicity testing of acellular pertussis vaccines.
Xing D; Maes A; Behr-Gross ME; Costanzo A; Daas A; Buchheit KH
Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):51-63. PubMed ID: 20223190
[TBL] [Abstract][Full Text] [Related]
16. Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model.
David S; van Furth R; Mooi FR
Vaccine; 2004 May; 22(15-16):1892-8. PubMed ID: 15121300
[TBL] [Abstract][Full Text] [Related]
17. Acellular Bordetella pertussis vaccine enhances mucosal interleukin-10 production, induces apoptosis of activated Th1 cells and attenuates colitis in Galphai2-deficient mice.
Ohman L; Willén R; Hultgren OH; Hultgren Hörnquist E
Clin Exp Immunol; 2005 Jul; 141(1):37-46. PubMed ID: 15958068
[TBL] [Abstract][Full Text] [Related]
18. Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study.
Reynolds E; Walker B; Xing D; Southern J; Asokanathan C; Dagg B; Corbel M; Miller E
Vaccine; 2006 Apr; 24(16):3248-57. PubMed ID: 16480794
[TBL] [Abstract][Full Text] [Related]
19. Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants.
Blennow M; Granström M
Pediatrics; 1989 Jul; 84(1):62-7. PubMed ID: 2544850
[TBL] [Abstract][Full Text] [Related]
20. Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis.
Sato H; Sato Y
Dev Biol Stand; 1985; 61():461-7. PubMed ID: 2872127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
